CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression

Sensitivity of CD95-mediated apoptosis has been reported to vary during cell cycle progression (FEBS Lett. (1997) 412, 91–93). Here, we report that three human glioma cell lines with different p53 status (i) undergo growth arrest and synchronous cell cycle re-entry after prolonged serum deprivation,...

Full description

Saved in:
Bibliographic Details
Published in:FEBS letters 1998-08, Vol.432 (3), p.155-157
Main Authors: Hueber, Arno, Durka, Silke, Weller, Michael
Format: Article
Language:English
Subjects:
Antibiotics, Antineoplastic - pharmacology
Antineoplastic Agents - pharmacology
Antineoplastic Agents, Phytogenic
Aphidicolin - pharmacology
Apoptosis
Apoptosis - drug effects
Apoptosis - immunology
Apoptosis - physiology
Camptothecin - pharmacology
CD95
Cell cycle
Cell Cycle - drug effects
Cell Cycle - physiology
Cell Death - drug effects
Cisplatin - pharmacology
Culture Media, Serum-Free - pharmacology
Doxorubicin - pharmacology
Enzyme Inhibitors - pharmacology
Fas Ligand Protein
fas Receptor - drug effects
fas Receptor - genetics
fas Receptor - physiology
Gene Expression - genetics
HeLa Cells
Humans
Hydroxyurea - pharmacology
Jurkat Cells - cytology
Jurkat Cells - drug effects
Jurkat Cells - metabolism
Membrane Glycoproteins - pharmacology
Nimustine - pharmacology
Nocodazole - pharmacology
Paclitaxel - pharmacology
Sensitivity and Specificity
Teniposide - pharmacology
Tumor Cells, Cultured - cytology
Tumor Cells, Cultured - drug effects
Tumor Cells, Cultured - metabolism
Vincristine - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sensitivity of CD95-mediated apoptosis has been reported to vary during cell cycle progression (FEBS Lett. (1997) 412, 91–93). Here, we report that three human glioma cell lines with different p53 status (i) undergo growth arrest and synchronous cell cycle re-entry after prolonged serum deprivation, (ii) do not exhibit cell cycle-related changes in CD95 expression at the cell surface, and (iii) do not exhibit cell cycle-related changes in susceptibility to DC95 ligand-induced apoptosis. In contrast, cell cycle-specific activity was demonstrated for various cancer chemotherapy drugs. Further, CD95 expression and susceptibility to CD95 ligand-induced apoptosis does not vary during cell cycle progression of Jurkat T cells, HeLa cervical carcinoma and HepG2 hepatocellular carcinoma cells. These results do not support a role for the cell cycle phase as an important predictor of vulnerability to CD95-mediated apoptosis.
ISSN:0014-5793
1873-3468
DOI:10.1016/S0014-5793(98)00855-2